The NORASEPT II study, as reported in The Lancet in 1998, and a 1995 JAMA study explored the potential of an anti-TNF-α monoclonal antibody (TNF-α MAb) for treating sepsis and septic shock, yielding critical insights into the challenges of targeting TNF-α in sepsis therapy [46,47]. Here, TNF is linked to Sepsis.